REGNRegeneron PharmaceuticalsNot started yet
A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult Participants
Secondary Stroke
5Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.8
5 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Worry score5
Score over time
- Stage
- Phase 3
- Patients
- 6,106 (planned)
- Started
- Nov 20, 2026
- Main results expected
- Dec 15, 2029
- Fully finished
- Dec 15, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Time to first occurrence of ischemic stroke
Measured over: Approximately 33 months
Time to first occurrence of International Society on Thrombosis and Haemostasis (ISTH) major bleeding
Measured over: Approximately 33 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07876492 · record last updated 2026-10-15 · checked 2026-11-09 15:47 UTC